Richard Anthony Cunningham - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
16 Sep 2022, 18:00:32 UTC
Prior SEC filing
26 Apr 2022
Next SEC filing
11 Oct 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: /s/ Richard Cunningham

Key filing fact

Richard Anthony Cunningham filed Form 4 for TYME TECHNOLOGIES, INC. on 16 Sep 2022.

Key facts

  • This page summarizes Richard Anthony Cunningham's Form 4 filing for TYME TECHNOLOGIES, INC..
  • 3 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 16 Sep 2022, 18:00.

Change

  • Previous filing in this sequence was filed on 26 Apr 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares
-2,000,000
Change %
-100%
Price
Shares after
0
Date
16 Sep 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,000,000
Exercise price
$1.03
Footnotes
F1
TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares
-500,000
Change %
-100%
Price
Shares after
0
Date
16 Sep 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
500,000
Exercise price
$1.43
Footnotes
F2
TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares
-1,326,000
Change %
-100%
Price
Shares after
0
Date
16 Sep 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,326,000
Exercise price
$0.3300
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Richard Anthony Cunningham is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 87,640 shares of Syros common stock for $23.51 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").

Footnote F2

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.

Footnote F3

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 58,105 shares of Syros common stock for $7.53 per share, after giving effect to the Reverse Split.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .